SecProbe.io

CORRESP
 1
 filename1.htm

 Curanex
Pharmaceuticals Inc

 2
Jericho Plaza, Suite 101B

 Jericho,
NY 11753

 April
8, 2025

 VIA
EDGAR

 U.S.
Securities and Exchange Commission

 Division
of Corporation Finance

 Office
of Technology

 100
F Street N.E.

 Washington,
D.C. 20549

 Attn:
Doris Stacey Gama and Chris Edward

 Re:

 Curanex
 Pharmaceuticals Inc
 Registration
 Statement on Form S-1, as amended (the "Registration Statement")
 File
 No. 333-282686
 Request
 for Acceleration of Effectiveness

 Ladies
and Gentlemen:

 Pursuant
to Rule 461 promulgated under the Securities Act of 1933, as amended (the "Act"), Curanex Pharmaceuticals Inc (the "Company")
hereby requests acceleration of the effectiveness of the above-referenced Registration Statement so that such Registration Statement
will become effective at 5:00 p.m. on April 9, 2025, or as soon thereafter as is practicable. In connection with such request, the undersigned
hereby acknowledges the following:

 1.
Should the Securities and Exchange Commission (the "Commission") or the staff, acting pursuant to delegated authority, declare
the filing effective, it does not foreclose the Commission from taking any action with respect to the filing.

 2.
The action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve
the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing.

 3.
The Company may not assert staff comments or the declaration of effectiveness as a defense in any proceeding initiated by the Commission
or any person under the federal securities laws of the United States.

 Sincerely,

 Curanex
 Pharmaceuticals Inc

 By:

 /s/
 Jun Liu

 Jun
 Liu

 Chief
 Executive Officer